European Biotech Acquisition Corp.
Johannes Vermeerplien 9
1071 DV Amsterdam, Netherlands
March 12, 2021
Division of Corporation Finance
Office of Real Estate & Construction
U.S. Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549-3233
| Attn: | Mr. Alan Campbell |
| Ms. Suzanne Hayes |
| Re: | European Biotech Acquisition Corp. Registration Statement on Form S-1 Registration No. 333-253220 |
Dear Mr. Campbell and Ms. Hayes:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant hereby requests that the effective date for the Registration Statement referred to above be accelerated so that it will be declared effective at 4:00 p.m. Eastern Standard Time on March 15, 2021 or as soon thereafter as is practicable. By separate letter, the underwriters of the issuance of the securities being registered join in this request for acceleration.
Please do not hesitate to contact Derek J. Dostal of Davis Polk & Wardwell LLP at (212) 450-4322 with any questions or comments with respect to this letter.
Sincerely,
| European Biotech Acquisition Corp. | |||
| By: | /s/ Eduardo Bravo | ||
| Name: | Eduardo Bravo | ||
Title: | Chief Executive Officer | ||
Via EDGAR
| CC: | Derek J. Dostal, Davis Polk & Wardwell LLP |
Yasin Keshvargar, Davis Polk & Wardwell LLP
